Current Report Filing (8-k)
10 March 2023 - 9:11AM
Edgar (US Regulatory)
0001860657
false
0001860657
2023-03-09
2023-03-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 9, 2023
ALLARITY THERAPEUTICS, INC.
(Exact
name of registrant as specified in our charter)
| Delaware |
|
001-41160 |
|
87-2147982 |
(State
or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification
No.) |
24
School Street, 2nd Floor,
Boston,
MA |
|
02108 |
| (Address
of Principal Executive Offices) |
|
(Zip
Code) |
(401)
426-4664
(Registrant’s
telephone number, including area code)
Not
applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common Stock, par value $0.0001 per share |
|
ALLR |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
7.01 Regulation FD Disclosure
On
March 9, 2023, Allarity Therapeutics, Inc. (the “Company”) is providing corporate presentation slides about the Company (the
“Corporate Presentation”). The Corporate Presentation
may be used in presentations to investors, analysts, and others. A copy of the Corporate Presentation is
attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The
information reported under Item 7.01 in this Current Report on Form 8-K, including Exhibit 99.1, is being “furnished” and
shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)
or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing. This Current Report on
Form 8-K will not be deemed an admission as to the materiality of any information contained herein.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
| Exhibit |
|
Exhibit
Description |
| 99.1 |
|
Corporate Presentation |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
Allarity
Therapeutics, Inc. |
| |
|
| |
By: |
/s/
James G. Cullem |
| |
|
James
G. Cullem |
| |
|
Chief Executive Officer |
| |
|
|
| Dated:
March 9, 2023 |
|
|
2
Allarity Therapeutics (NASDAQ:ALLR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allarity Therapeutics (NASDAQ:ALLR)
Historical Stock Chart
From Apr 2023 to Apr 2024
